Challenge:
A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS indications, had been extensively tested in Phase II and an inconclusive Phase III study, and the investor needed to understand whether the rationale and current understanding of the product, taken together with the totality of data developed to date, provided sufficient support for investing in a further pivotal trial.
Solution:
Alacrita's engaged two CNS therapeutic experts from its consulting network who were able to provide the appropriate therapeutic perspective and experience-based judgement to enable an estimate of the probability of success of Phase III trials in the two selected indications. Based on this due diligence input, the investment proceeded.
Our Expertise with CNS Therapeutics
We've consulted with clients on a range of CNS drug development products and programs, and have advised investors and BD teams on individual assets, pipelines and companies in this field.